Metabolomic distinction of microvascular effects of lipoprotein apheresis - A pilot study

Atherosclerosis Supplements

Volumn 14, Issue 1, 2013, Pages 143-149

  Reimann, M ^a   Peitzsch, M ^a   Ziemssen, T ^a   Julius, U ^a   Eisenhofer, G ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Cardiovascular disease; Endothelial function; Lipoprotein apheresis; Metabolomics

Indexed keywords

CARNITINE DERIVATIVE; DALI; DICARBOXYACYLCARNITINE; HEPARIN; LF; LIPOPROTEIN; LYSOPHOSPHATIDYLCHOLINE; METHIONINE; ORNITHINE; SERINE; UNCLASSIFIED DRUG;

ADULT; AGED; APHERESIS; ARTICLE; BLOOD SAMPLING; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DECISION TREE; DIAGNOSTIC TEST ACCURACY STUDY; ELECTROSPRAY MASS SPECTROMETRY; ENDOTHELIUM; FEMALE; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; MALE; MASS SPECTROMETRY; METABOLITE; METABOLOME; METABOLOMICS; MICROVASCULARIZATION; PILOT STUDY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETINA; RETINA BLOOD VESSEL; RETINA ENDOTHELIAL; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD COMPONENT REMOVAL; CARNITINE; CHI-SQUARE DISTRIBUTION; DECISION TREES; FEMALE; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS; LYSOPHOSPHATIDYLCHOLINES; MALE; METABOLOMICS; METHIONINE; MICROVESSELS; MIDDLE AGED; ORNITHINE; PHOTIC STIMULATION; PILOT PROJECTS; RETINAL VESSELS; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SERINE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME;

EID: 84872864593     PISSN: 15675688     EISSN: 18785050     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2012.10.008     Document Type: Article

References (27)

1. Shah S.H., Hauser E.R., Bain J.R., et al. High heritability of metabolomic profiles in families burdened with premature cardiovascular disease. Mol Syst Biol 2009, 5:258.
2. Shah S.H., Bain J.R., Muehlbauer M.J., et al. Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circ Cardiovasc Genet 2010, 3:207-214.
3. Turer A.T., Stevens R.D., Bain J.R., et al. Metabolomic profiling reveals distinct patterns of myocardial substrate use in humans with coronary artery disease or left ventricular dysfunction during surgical ischemia/reperfusion. Circulation 2009, 119:1736-1746.
4. Mayr M., Yusuf S., Weir G., et al. Combined metabolomic and proteomic analysis of human atrial fibrillation. J Am Coll Cardiol 2008, 51:585-594.
5. Sabatine M.S., Liu E., Morrow D.A., et al. Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 2005, 112:3868-3875.
6. Lewis G.D., Wei R., Liu E., et al. Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. J Clin Invest 2008, 118:3503-3512.
7. Julius U., Frind A., Tselmin S., Kopprasch S., Poberschin I., Siegert G. Comparison of different LDL apheresis methods. Expert Rev Cardiovasc Ther 2008, 6:629-639.
8. Julius U., Tselmin S., Fischer S., Passauer J., Bornstein S.R. The Dresden Apheresis Center - experience with LDL apheresis and immunoadsorption. Atheroscler Suppl 2009, 10:12-16.
9. Reimann M., Prieur S., Lippold B., et al. Retinal vessel analysis in hypercholesterolemic patients before and after LDL apheresis. Atheroscler Suppl 2009, 10:39-43.
10. Tamai O., Matsuoka H., Itabe H., Wada Y., Kohno K., Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997, 95:76-82.
11. Tselmin S., Schmitz G., Julius U., Bornstein S.R., Barthel A., Graessler J. Acute effects of lipid apheresis on human serum lipidome. Atheroscler Suppl 2009, 10:27-33.
12. Pournaras C.J., Rungger-Brandle E., Riva C.E., Hardarson S.H., Stefansson E. Regulation of retinal blood flow in health and disease. Prog Retin Eye Res 2008, 27:284-330.
13. Altmaier E., Kastenmuller G., Romisch-Margl W., et al. Questionnaire-based self-reported nutrition habits associate with serum metabolism as revealed by quantitative targeted metabolomics. Eur J Epidemiol 2011, 26:145-156.
14. Weinberger K.M. Metabolomics in diagnosing metabolic diseases. Ther Umsch 2008, 65:487-491.
15. Reimann M., Julius U., Haink K., et al. LDL apheresis improves deranged cardiovagal modulation in hypercholesterolemic patients. Atherosclerosis 2010, 213:212-217.
16. Wiesner P., Leidl K., Boettcher A., Schmitz G., Liebisch G. Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry. J Lipid Res 2009, 50:574-585.
17. Schmitz G., Ruebsaamen K. Metabolism and atherogenic disease association of lysophosphatidylcholine. Atherosclerosis 2010, 208:10-18.
18. Taha T.A., Hannun Y.A., Obeid L.M. Sphingosine kinase: biochemical and cellular regulation and role in disease. J Biochem Mol Biol 2006, 39:113-131.
19. Uchida Y., Kawai S., Kanamaru R., Kameda N. Imaging of lysophosphatidylcholine in human coronary plaques by color fluorescence angioscopy. Int Heart J 2010, 51:129-133.
20. Matsuzaki M., Hiramori K., Imaizumi T., et al. Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART). J Am Coll Cardiol 2002, 40:220-227.
21. Nishimura S., Sekiguchi M., Kano T., et al. Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS). Atherosclerosis 1999, 144:409-417.
22. Chalmers R.A., Roe C.R., Stacey T.E., Hoppel C.L. Urinary excretion of l-carnitine and acylcarnitines by patients with disorders of organic acid metabolism: evidence for secondary insufficiency of l-carnitine. Pediatr Res 1984, 18:1325-1328.
23. Lavi S., McConnell J.P., Rihal C.S., et al. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation 2007, 115:2715-2721.
24. Stuhlinger M.C., Oka R.K., Graf E.E., et al. Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. Circulation 2003, 108:933-938.
25. Sydow K., Schwedhelm E., Arakawa N., et al. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins. Cardiovasc Res 2003, 57:244-252.
26. Wheeler-Jones C.P. Cell signalling in the cardiovascular system: an overview. Heart 2005, 91:1366-1374.
27. Mellwig K.P., van Buuren F., Schmidt H.K., Wielepp P., Burchert W., Horstkotte D. Improved coronary vasodilatatory capacity by H.E.L.P. apheresis: comparing initial and chronic treatment. Ther Apher Dial 2006, 10:510-517.